A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain

NeuroReport

Volumn 27, Issue 6, 2016, Pages 384-391

  Cao, Lijun ^b   Li, Dongfang ^b   Feng, Peng ^b   Li, Lin ^b   Xue, Guo Fang ^b   Li, Guanglai ^b   Hölscher, Christian ^a,b  

^a LANCASTER UNIVERSITY   (United Kingdom)

^b SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Basal ganglia; Growth factor; Incretins; Inflammation; Insulin; Neurodegeneration

Indexed keywords

ANTIPARKINSON AGENT; DA-JC1 PEPTIDE; NEUROPROTECTIVE AGENT; PEPTIDE DERIVATIVE; SYNAPTOPHYSIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; AIF1 PROTEIN, MOUSE; CALCIUM BINDING PROTEIN; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; GLP1R PROTEIN, MOUSE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HORMONE RECEPTOR; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN TISSUE; CHRONIC INFLAMMATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; EXPLORATORY BEHAVIOR; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOUSE; MUSCLE STRENGTH; NEUROPROTECTION; NONHUMAN; OPEN FIELD BEHAVIOR; OPEN FIELD TEST; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ROTAROD TEST; SUBSTANTIA NIGRA; SYNAPSE; TRACTION TEST; AGONISTS; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; LOCOMOTION; METABOLISM; MPTP POISONING; PATHOLOGY;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; BRAIN; CALCIUM-BINDING PROTEINS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; LOCOMOTION; MALE; MICE; MICE, INBRED C57BL; MICROFILAMENT PROTEINS; MPTP POISONING; PEPTIDES; RECEPTORS, GASTROINTESTINAL HORMONE; TYROSINE 3-MONOOXYGENASE;

EID: 84959239661     PISSN: 09594965     EISSN: 1473558X     Source Type: Journal    
DOI: 10.1097/WNR.0000000000000548     Document Type: Article

References (39)

1. Langston JW. Parkinson's disease: current and future challenges. Neurotoxicology 2002; 23:443-450.
2. Mickiewicz AL, Kordower JH. GDNF family ligands: a potential future for Parkinson's disease therapy. CNS Neurol Disord Drug Targets 2011; 10:703-711.
3. Hölscher C. Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases. Biochem Soc Trans 2014; 42:593-599.
4. Perry TA, Greig NH. A new Alzheimer's disease interventive strategy: GLP-1. Curr Drug Targets 2004; 5:565-571.
5. Hölscher C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol 2014; 221:31-41.
6. Bertilsson G, Patrone C, Zachrisson O, Andersson A, Dannaeus K, Heidrich J, et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res 2008; 86:326-338.
7. Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflammation 2008; 5:19.
8. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 2009; 106:1285-1290.
9. Kim S, Moon M, Park S. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J Endocrinol 2009; 202:431-439.
10. Finan B, Ma T, Ottaway N, Müller TD, Habegger KM, Heppner KM, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med 2013; 5:209ra151.
11. Faivre E, Hölscher C. Neuroprotective effects of D-Ala(2)GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model. Alzheimers Res Ther 2013; 5:20.
12. Duffy AM, Hölscher C. The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease. Neuroscience 2013; 228:294-300.
13. Hölscher C. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease. Alzheimers Dement 2014; 10 (Suppl):S47-S54.
14. Nakamura S, Vincent SR. Histochemistry of MPTP oxidation in the rat brain: sites of synthesis of the Parkinsonism-inducing toxin MPP + . Neurosci Lett 1986; 65:321-325.
15. Gerlach M, Riederer P, Przuntek H, Youdim MB. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol 1991; 208:273-286.
16. Kopin IJ, Markey SP. MPTP toxicity: implications for research in Parkinson's disease. Annu Rev Neurosci 1988; 11:81-96.
17. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2010; 37:510-518.
18. Luo FC, Wang SD, Qi L, Song JY, Lv T, Bai J. Protective effect of panaxatriol saponins extracted from Panax notoginseng against MPTP-induced neurotoxicity in vivo. J Ethnopharmacol 2011; 133:448-453.
19. Bondolfi L, Calhoun M, Ermini F, Kuhn HG, Wiederhold KH, Walker L, et al. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci 2002; 22:515-522.
20. Morin N, Jourdain VA, Di Paolo T. Modeling dyskinesia in animal models of Parkinson disease. Exp Neurol 2014; 256:105-116.
21. Han L, Hölscher C, Xue G-F, Li G, Li D. A novel dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischaemia in the rat. Neuroreport 2015; 27:23-32.
22. Ji C, Xue GF, Lijun C, Feng P, Li D, Li L, et al. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF. Brain Res 2015. [Epub ahead of print].
23. Boncristiano S, Calhoun ME, Howard V, Bondolfi L, Kaeser SA, Wiederhold KH, et al. Neocortical synaptic bouton number is maintained despite robust amyloid deposition in APP23 transgenic mice. Neurobiol Aging 2005; 26:607-613.
24. Nagatsu T, Mogi M, Ichinose H, Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl 2000; 58:277-290.
25. Greig NH, Mattson MP, Perry T, Chan SL, Giordano T, Sambamurti K, et al. New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists. Ann N Y Acad Sci 2004; 1035:290-315.
26. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002; 22:1763-1771.
27. Sato K, Kameda M, Yasuhara T, Agari T, Baba T, Wang F, et al. Neuroprotective effects of liraglutide for stroke model of rats. Int J Mol Sci 2013; 14:21513-21524.
28. Darsalia V, Mansouri S, Ortsäter H, Olverling A, Nozadze N, Kappe C, et al. Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in type 2 diabetic rats. Clin Sci (Lond) 2012; 122:473-483.
29. Tweedie D, Rachmany L, Rubovitch V, Lehrmann E, Zhang Y, Becker KG, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. Exp Neurol 2013; 239:170-182.
30. McClean PL, Hölscher C. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease. Neuropharmacology 2014; 86:241-258.
31. Liu W, Jalewa J, Sharma M, Li G, Li L, Hölscher C. Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neuroscience 2015; 303:42-50.
32. Zhang Y, Chen Y, Li L, Hölscher C. Neuroprotective effects of (Val8) GLP-1-Glu-PAL in the MPTP Parkinson's disease mouse model. Behav Brain Res 2015; 293:107-113.
33. Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, et al. Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest 2013; 123:2730-2736.
34. Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Ell P, et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J Parkinsons Dis 2014; 4:337-344.
35. Faivre E, Gault VA, Thorens B, Hölscher C. Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis. J Neurophysiol 2011; 105:1574-1580.
36. Faivre E, Hölscher C. D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model. J Alzheimers Dis 2013; 35:267-283.
37. Ji C, Xue GF, LI G, Li D, Hölscher C. Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease. Rev Neurosci 2016; 27:61-70.
38. Giráldez-Pérez R, Antolín-Vallespín M, Muñoz M, Sánchez-Capelo A. Models of α-synuclein aggregation in Parkinson's disease. Acta Neuropathol Commun 2014; 2:176.
39. Bobela W, Zheng L, Schneider BL. Overview of mouse models of Parkinson's disease. Curr Protoc Mouse Biol 2014; 4:121-139.